Successful Treatment of Acute Respiratory Distress Syndrome from Hydrofluoric Acid Inhalation

Xiaolei Liu¹, Baohong Yang¹, Ting Liu², Xiang Po Pan³, Kaiyu Sun²*

¹ Department of Oncology, Weifang People’s Hospital, Weifang, Shandong 261041, P.R. China.
² Weifang medical university, Weifang Shandong 261041, P.R. China.
³ Department of Clinical laboratory, Weifang People’s Hospital, Weifang Shandong 261041, P.R. China.

Corresponding Author: Kaiyu Sun, Weifang medical university, Weifang Shandong 261041, P.R. China. Email: baohongy@me.com, telephone: 13173105598


Copyright: © 2017 Kaiyu Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received March 30, 2017 Accepted May 06, 2017 Published July 03, 2017

Abstract

Hydrofluoric acid (HF) is an industrial chemical widely used in many industries, including industries of the aluminum, steel, fertilier, glass, ceramic, and brick. In a variety of settings, HF is a pollutant usually created in an industrial process (1). Studies showed that concentrated HF contamination may cause a fatal outcome even if small areas of body surface are exposed (2,3). The case reported here is acute respiratory distress syndrome (ARDS) due to accidental inhalation of HF. In cases of refractory hypoxemia, extracorporeal membrane oxygenation (ECMO) is becoming an acceptable rescue therapy. We believe severe hypoxic respiratory failure as a result of ARDS caused by inhalation of HF in which venovenous-ECMO (VV-ECMO) was used successfully as a bridge to lung recovery has not been previous reported.

Keywords: Hydrofluoric acid; Inhalation; ARDS; ECMO

Introduction

A 38-year-old Chinese male mechanist who suffered an accidental inhalation of HF from a broken transmission pipe during his working in an aluminum industry started coughing and hemoptysis after approximately 2 hours HF exposure. And he was immediately sent to the local emergency department. The initial chest CT scan showed there were severe patchy infiltrates throughout both lungs of the patient’s as showed in figure 1. The patient was transferred to the intensive care unit for definitive management after the quick medical laboratory examination. The inquiry of the patient showed that he was previous healthy without any systemic illnesses or drug allergies, no history of smoking or regular alcohol consumption. Physical examination revealed a body temperature of 37°C, a pulse of 120 beats per minute, and a blood pressure of 100/60 mmHg. Examination of the lungs found decreased breath sounds with occasional wheezes and rales. The electrocardiogram and echocardiogram did not reveal any abnormalities. Chemistry laboratory test showed a red blood cell count of 4.34×10⁹/12/L, a white blood cell count of 25.96×10⁹/12/L (granulocytes 92.5%) and a platelet count of 120×10⁹/12/L. The serum level of creatinine was 79 umol/l (reference range: 45–116 umol/l), blood urea nitrogen 8.7 mmol/l (range: 2.7–8.5 mmol/l), sodium 142 mmol/L, calcium 1.93 mmol/L (range: 2.10–2.70 mmol/L), magnesium 0.85 mmol/L (range: 0.72–1.21 mmol/L), potassium 4.99 mmol/L, glucose 7.7 mmol/l (range: 3.9–6.1 mmol/l), cardiac isoenzyme of creatine kinase 18 U/L (range: 0–20 U/L), and creatine kinase 878 U/L (range: 38–174 U/L). Initial laboratories showed hypocalcemia, the blood gas (ABG) revealed a metabolic acidosis (pH 7.32, base deficit 9, HCO₃ 16) and a PO2/FiO2 ratio 90, which is consistent

Figure 1. Initial chest CT scan showing severe patchy infiltrates throughout both lungs
with adult respiratory distress syndrome (ARDS).

A chest x-ray was performed in our unit immediately after arrival, and the chest x-ray showed severe patchy infiltrates throughout both lungs as in Figure 2.

Besides critical care and ventilatory support, we started the treatment with nebulized calcium gluconate (2.5%) for the first 3 hours continuously and then every 4 hours. We serially monitored electrolytes every 8 hours. After 48 hours, the patient did not have significant calcium requirements and the nebulized calcium gluconate was discontinued. His initial EKG was unremarkable, subsequent EKGs performed after his admission did not reveal any abnormalities.

Considering the patients temperature was increasing and WBC rising, therapy with ampicillin was begun empirically and was later changed to piperacillin when cultures of the sputum grew coagulase-positive Staphylococcus aureus resistant to ampicillin. Blood cultures grew no organisms.

In the first 48 hours, Ventilatory support were made and adjusted occasionally based on arterial blood gases and oxygen saturation. By hospital day 3, the patient’s pulmonary function was deteriorating and the PaO2/FIO2 ratio is only 59 mmHg while on a conventional ventilator with synchronized intermittent mandatory ventilation plus pressure support. We decided to initiate extracorporeal membrane oxygenation (ECMO).

Appropriate consent for initiation of VV-ECMO was obtained and the right internal jugular vein was cannulated with a 27F Avalon Elite cannula (Maquet Cardiobelp HLS device) within 2 hours. Initial VV-ECMO flows were 3 L/min with a sweep ow of 2.5 L/min at 100% FiO2. Settings were subsequently titrated to clinical status. After VV-ECMO initiation, the patient was placed on pressure control ventilation with 15cm H2O of PEEP and inspiratory pressure of 25cm H2O.

Four days after supportive therapy, the patient was weaned successfully from VV-ECMO support. Chest X-ray scan showed a resolving ARDS-type pattern (Fig.3). By hospital day 10, the patient was transferred to the ward, he continued to need ventilatory support and subsequently underwent tracheostomy placement. After 4 weeks on the ventilator, ventilatory support was withdrawn considering he tolerated breathing via his tracheostomy for more than 24 hours. On hospital day 37, he was discharged from the hospital with no infiltrates in the lungs (Fig.4).

**Discussion**

After inhalation of HF, the highly reactive fluoride ion forms complexes mainly with calcium which can result in severe hypocalcemia, leading to myocardial irritability or dysrhythmias (4). Most published case reports showed that exposure to HF producing hypocalcemia and hypomagnesemia, usually accompanied by hyperkalemia (5). The patient in this case report presented with hypocalcemia, but no hypomagnesemia or hypokalemia, which is unusual.

Calcium gluconate was widely used in cutaneous HF exposure (6). However, only a few case reports showing the use of calcium gluconate in HF inhalational exposures (7). Further clinical studies are necessary.
Acute lung injury resulting in noncardiogenic pulmonary edema after exposure to HF has not previously been reported. When HF was exposed to the upper airways of the rodent models, HF would enter into the systemic circulation rapidly. A very small quantity of HF gas exposure always causing serious problem. The research showed that HF delivered to the lower airways directly caused significant pulmonary hemorrhage and edema (8). The development of syndromes have been consistent with studies done in human volunteers (9).

After failure of conventional modes of ventilation in patients with inhalational injury, the decision to initiate ECMO for this patient was influenced by the recent evidences of ARDS management including early application of ECMO (10,11). In the CESAR trial, indications for initiating ECLS were adult patients (18 – 65 years) who had severe but potentially reversible respiratory failure and uncompensated hypercapnea with a pH 7.20 or a Murray score 3.0. The patient we reported here met the criteria outlined by the CESAR trial (38 years, PaO2/FiO2 ratio 59 despite maximal conventional therapy, and Murray score 3.5).

Conclusion: This case highlights the complexity of treating an inhalation injury from HF. This patient survived, despite the fact that ARDS caused by severe inhalation injuries of HF have been fatal, VV-ECMO should be considered when conventional treatments fail in treating refractory hypoxemia.

Conflict of interest: None

References